- Email: [email protected]
1.159 Weight loss and adiponectin levels in patients with Parkinson's disease
Poster Presentations: Parkinsonism subjects were significant higher than that of the PD patients (P < 005). But Fe, Mn of PD patients was higher than that of the control subjects (P < 005). Logistic analysis presents such a result: high animal fat acid intake, depress, Vit E levels were hazard factors of PD development, OR: 1.98 (95% CI: 1.06−1.35), 39.12 (95% CI: 1.90−8.26), 1.74 (95% CI: 1.23−2.46), respectively. High social class and more milk intake were protective factors of PD development: OR: 0.06 (95% CI: 0.002−0.25), 0.86 (95% CI: 0.75−0.99), respectively. Conclusion: Development of Parkinson’s disease was highly relative with nutritional status, depress, further study should focus on it.
1.159 Weight loss and adiponectin levels in patients with Parkinson’s disease Y. Tsuboi1° , Y. Uehara, Y. Baba, T. Kobayashi, T. Yamada Japan
1 Fukuoka,
Objective: Weight loss is one of non-motor symptoms associated with Parkinson’s disease (PD). Adiponectin is a protein secreted by adipose tissue that related with insulin resistance and anti-atherosclerosis effect. In this study, we investigated the relationship between weight loss and adiponetin in patients with PD. Method: We evaluated serum adiponectin levels and weight changes in before and after of the onset in 43 PD cases. Weight loss is assessed with body mass index (BMI) changes between 5 years before and after the onset. Results: Significant weight loss (>1.5 BMI loss during the course of the disease) happened in 17 cases (39.5%). Mild weight loss (0.5−1.5 BMI loss during the course of the disease) is seen in 10 cases (23.2%). BMI is not associated with adiponectin level, whereas weight loss is positively associated with adiponectin level (r = 0.374, p = 0.006). Conclusion: Weight loss but not BMI is associated with adiponectin level. These results indicate that adiponectin related lipid metabolic changes occur in the course of the illness in PD patients with weight loss. Further investigation should be done to clarify the lipid metabolism abnormalities in this disorder.
1.160 Serum leptin and ghrelin concentrations in Parkinson’s disease patients with and without weight loss U. Fiszer1° , M. Michalowska, B. Baranowska, E. Wolinska-Witort, W. Jeske, M. Jethon 1 Warsaw, Poland Objective: Parkinson’s disease (PD) is commonly associated with unintended weight loss, and may be related to different factors. The aim of the study was to investigate the role of peptides (leptin and ghrelin) and hormones (GH and IGF-1) in energy balance disturbances in PD. Method: The study population comprised 39 patients: 11 in the group of PD patients with unintentional loss of weight, 16 in the group of PD patients without loss of weight and 12 in the age-matched control group. Patients were evaluated using the Hoehn and Yahr scale and UPDRS (PD patients), MMSE, MADRS and the appetite scale. In all patients the body mass index was calculated, and the serum TSH, T3, T4, leptin, ghrelin, GH and IGF-1 levels were measured. T-Student test, chi-square test and Pearson’s linear correlation analysis were used. Results: A lower serum leptin concentration was found in PD patients with loss of weight in comparison with the control group. This finding was not associated with upper serum ghrelin level in these patients, and satiety rating. The serum IGF-1 level was higher in PD patients with loss of weight in comparison with PD patients without loss of weight and controls. There was no correlation between leptin, ghrelin, GH and IGF-1 levels in both groups of PD patients. Conclusion: The mechanism behind the course of unintended weight loss in PD is still poorly understood, several putative reasons can be proposed. Dopamine has been reported to play an important role in the regulation of food intake. Dopaminergic dysfunction, however, cannot
S49
fully explain unintended weight loss in human, since chronic levodopa treatment fails to uniformly cause weight gain. However, deficiency in hypothalamic dopamine transmission in PD could alter central sensitivity to the effects of leptin. Circulating ghrelin does not play an important role in the modification of weight homeostasis in PD patients.
1.161 Plasma homocysteine concentration and peripheral neuropathy in Parkinson’s disease patients: A pilot study M. Nevrly1° , H. Vranova, Z. Chovancova, I. Nestrasil, P. Otruba, J. Dufek, P. Kanovsky 1 Olomouc, Czech Republic Objective: Homocysteine (Hcy) is a risk factor for vascular diseases, dementia, and cognitive impairment. Elevated plasma Hcy levels have been found in PD patients treated with L-dopa. However, elevated Hcy plasma level is also considered a neurotoxic factor, inducing a predominantly axonal degeneration in peripheral nerves (Muller et al., 2004). Method: The assessment of sensory nerve conduction velocity (SNCV) and sensory nerve action potentials (SNAP) of the right sural nerve and the left peroneal superficial nerve, assessment of motor nerve conduction velocity (MNCV) and motor nerve action potentials (MNAP) of the right tibial nerve and left peroneal nerve and assessment of H-reflexes latency of the bilateral tibial nerves were performed in 18 PD patients (aged 29−73, mean 61.8±10.3 years). Hcy plasma levels were also examined in all of these patients. Results: Plasma Hcy levels in the patient group were: 13.3±4.4 (6.2−22.6) – mean±SD (min–max) (mmol/l). 10 patients (55.6%) had elevated plasma Hcy level more than 12 mmol/l (Stanger et al., 2003). Abnormal SNCV (<45 m·s−1 ) was found in 9 patients at right sural nerve and in 10 patients at left superficial peroneal nerve. Abnormal MNCV (<40 m·s−1 ) was found in 4 patients at right tibial nerve and in 3 patients at left peroneal nerve. The data were analyzed by Pearson correlation and there was found correlation between MNCV at left peroneal nerve and Hcy plasma concentration. Conclusion: Although hyperhomocysteinemia is considered a neurotoxic factor, results of this study do not confirm this hypothesis unambiguously. The possible correlation of elevated Hcy plasma levels and demyelinating degradation of peroneal nerve has to be confirmed by studies with larger number of patients and with the examination of more peripheral nerves than in this study.
1.162 Risk factor of mental disorders in Parkinson disease L. Bolokadze1° 1 Kharkov, Ukraine Objective: To study the relationships between clinical features of Parkinson’s disease (PD) and the development of dementia, depression or psychosis in patients with long-standing disease. Method: 87 consecutive patients (40 men and 47 women, mean age at symptoms onset 46.4±14.7 years) with 3 years or more of PD (mean symptom duration of 10.9±4.8 years) were studied. Clinical data were collected during the last office visit through physical examination, detailed history, review of patient charts and outside documents. Results: 37% had dementia, 36% patients had depression and 29% had psychosis. Dementia and depression were significantly associated with disease severity as reflected in the Hoehn & Yahr scale (P = 0.0008, Z = 4.19; P = 0.007, Z = 2.31, respectively). These associations were significant also for the older age of PD onset (50 years n = 57) subgroup (p = 0.004, Z = 2.2 for dementia and p = 0.04, Z = 3.9 for depression), but not for younger onset cases (<59 years n = 30). The presence of dementia was also significantly associated with depression. Dementia and depression were found to be independent explanatory variables for the development of psychosis (logistic regression, odds ratio (OR) = 24.0, p < 0.0001; OR = 11.6,
1.159 Weight loss and adiponectin levels in patients with Parkinson’s disease Y. Tsuboi1° , Y. Uehara, Y. Baba, T. Kobayashi, T. Yamada Japan
1 Fukuoka,
Objective: Weight loss is one of non-motor symptoms associated with Parkinson’s disease (PD). Adiponectin is a protein secreted by adipose tissue that related with insulin resistance and anti-atherosclerosis effect. In this study, we investigated the relationship between weight loss and adiponetin in patients with PD. Method: We evaluated serum adiponectin levels and weight changes in before and after of the onset in 43 PD cases. Weight loss is assessed with body mass index (BMI) changes between 5 years before and after the onset. Results: Significant weight loss (>1.5 BMI loss during the course of the disease) happened in 17 cases (39.5%). Mild weight loss (0.5−1.5 BMI loss during the course of the disease) is seen in 10 cases (23.2%). BMI is not associated with adiponectin level, whereas weight loss is positively associated with adiponectin level (r = 0.374, p = 0.006). Conclusion: Weight loss but not BMI is associated with adiponectin level. These results indicate that adiponectin related lipid metabolic changes occur in the course of the illness in PD patients with weight loss. Further investigation should be done to clarify the lipid metabolism abnormalities in this disorder.
1.160 Serum leptin and ghrelin concentrations in Parkinson’s disease patients with and without weight loss U. Fiszer1° , M. Michalowska, B. Baranowska, E. Wolinska-Witort, W. Jeske, M. Jethon 1 Warsaw, Poland Objective: Parkinson’s disease (PD) is commonly associated with unintended weight loss, and may be related to different factors. The aim of the study was to investigate the role of peptides (leptin and ghrelin) and hormones (GH and IGF-1) in energy balance disturbances in PD. Method: The study population comprised 39 patients: 11 in the group of PD patients with unintentional loss of weight, 16 in the group of PD patients without loss of weight and 12 in the age-matched control group. Patients were evaluated using the Hoehn and Yahr scale and UPDRS (PD patients), MMSE, MADRS and the appetite scale. In all patients the body mass index was calculated, and the serum TSH, T3, T4, leptin, ghrelin, GH and IGF-1 levels were measured. T-Student test, chi-square test and Pearson’s linear correlation analysis were used. Results: A lower serum leptin concentration was found in PD patients with loss of weight in comparison with the control group. This finding was not associated with upper serum ghrelin level in these patients, and satiety rating. The serum IGF-1 level was higher in PD patients with loss of weight in comparison with PD patients without loss of weight and controls. There was no correlation between leptin, ghrelin, GH and IGF-1 levels in both groups of PD patients. Conclusion: The mechanism behind the course of unintended weight loss in PD is still poorly understood, several putative reasons can be proposed. Dopamine has been reported to play an important role in the regulation of food intake. Dopaminergic dysfunction, however, cannot
S49
fully explain unintended weight loss in human, since chronic levodopa treatment fails to uniformly cause weight gain. However, deficiency in hypothalamic dopamine transmission in PD could alter central sensitivity to the effects of leptin. Circulating ghrelin does not play an important role in the modification of weight homeostasis in PD patients.
1.161 Plasma homocysteine concentration and peripheral neuropathy in Parkinson’s disease patients: A pilot study M. Nevrly1° , H. Vranova, Z. Chovancova, I. Nestrasil, P. Otruba, J. Dufek, P. Kanovsky 1 Olomouc, Czech Republic Objective: Homocysteine (Hcy) is a risk factor for vascular diseases, dementia, and cognitive impairment. Elevated plasma Hcy levels have been found in PD patients treated with L-dopa. However, elevated Hcy plasma level is also considered a neurotoxic factor, inducing a predominantly axonal degeneration in peripheral nerves (Muller et al., 2004). Method: The assessment of sensory nerve conduction velocity (SNCV) and sensory nerve action potentials (SNAP) of the right sural nerve and the left peroneal superficial nerve, assessment of motor nerve conduction velocity (MNCV) and motor nerve action potentials (MNAP) of the right tibial nerve and left peroneal nerve and assessment of H-reflexes latency of the bilateral tibial nerves were performed in 18 PD patients (aged 29−73, mean 61.8±10.3 years). Hcy plasma levels were also examined in all of these patients. Results: Plasma Hcy levels in the patient group were: 13.3±4.4 (6.2−22.6) – mean±SD (min–max) (mmol/l). 10 patients (55.6%) had elevated plasma Hcy level more than 12 mmol/l (Stanger et al., 2003). Abnormal SNCV (<45 m·s−1 ) was found in 9 patients at right sural nerve and in 10 patients at left superficial peroneal nerve. Abnormal MNCV (<40 m·s−1 ) was found in 4 patients at right tibial nerve and in 3 patients at left peroneal nerve. The data were analyzed by Pearson correlation and there was found correlation between MNCV at left peroneal nerve and Hcy plasma concentration. Conclusion: Although hyperhomocysteinemia is considered a neurotoxic factor, results of this study do not confirm this hypothesis unambiguously. The possible correlation of elevated Hcy plasma levels and demyelinating degradation of peroneal nerve has to be confirmed by studies with larger number of patients and with the examination of more peripheral nerves than in this study.
1.162 Risk factor of mental disorders in Parkinson disease L. Bolokadze1° 1 Kharkov, Ukraine Objective: To study the relationships between clinical features of Parkinson’s disease (PD) and the development of dementia, depression or psychosis in patients with long-standing disease. Method: 87 consecutive patients (40 men and 47 women, mean age at symptoms onset 46.4±14.7 years) with 3 years or more of PD (mean symptom duration of 10.9±4.8 years) were studied. Clinical data were collected during the last office visit through physical examination, detailed history, review of patient charts and outside documents. Results: 37% had dementia, 36% patients had depression and 29% had psychosis. Dementia and depression were significantly associated with disease severity as reflected in the Hoehn & Yahr scale (P = 0.0008, Z = 4.19; P = 0.007, Z = 2.31, respectively). These associations were significant also for the older age of PD onset (50 years n = 57) subgroup (p = 0.004, Z = 2.2 for dementia and p = 0.04, Z = 3.9 for depression), but not for younger onset cases (<59 years n = 30). The presence of dementia was also significantly associated with depression. Dementia and depression were found to be independent explanatory variables for the development of psychosis (logistic regression, odds ratio (OR) = 24.0, p < 0.0001; OR = 11.6,